Fertility and Sterility
Volume 91, Issue 4 , Pages 1067-1076, April 2009

Cost-saving treatment strategies in in vitro fertilization: a combined economic evaluation of two large randomized clinical trials comparing highly purified human menopausal gonadotropin and recombinant follicle-stimulating hormone alpha

  • Jaroslaw Wechowski, M.D., Ph.D.

      Affiliations

    • Health Economics, Cardiff Research Consortium, Cardiff, United Kingdom
    • ,
  • Mark Connolly, M.Sc.

      Affiliations

    • Health Economics, Ferring International Center, St. Prex, Switzerland
    • Corresponding Author InformationReprint requests: Mark Connolly, Director Market Access, Ferring International Center SA, Chemin de Vergognausaz 50, CH-1162, St. Prex, Switzerland (FAX: 41-0-58-301-0371).
    • ,
  • Dirk Schneider, M.D.

      Affiliations

    • Health Economics, Ferring International Center, St. Prex, Switzerland
    • ,
  • Philip McEwan, Ph.D.

      Affiliations

    • School of Mathematics, Cardiff University, Cardiff, United Kingdom
    • ,
  • Richard Kennedy, M.D.

      Affiliations

    • Centre for Reproductive Medicine, University Hospital, Coventry, United Kingdom

Received 8 October 2007; received in revised form 8 January 2008; accepted 8 January 2008. published online 12 March 2008.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This study was funded by Ferring Pharmaceuticals, St. Prex, Switzerland.

 Dr. Jaroslaw Wechowski and Dr. Philip McEwan are academic consultants who provide health-consulting services to pharmaceutical and medical device companies and governments. Dr. Jaroslaw Wechowski is the owner of Pharmarchitecture Limited, a consultancy for pharmaceutical companies not involved in the current study. Dr. Richard Kennedy is clinical director of the University Hospital Centre for Reproductive Medicine in Coventry and has worked as a nonremunerated advisor to this project. Mark Connolly and Dirk Schneider are employees of Ferring Pharmaceuticals.

 The results of this study were presented in an abbreviated format at the European Society for Human Reproduction and Embryology meeting, which was held in Lyon, France, in July 2007.

PII: S0015-0282(08)00041-1

doi:10.1016/j.fertnstert.2008.01.034

Fertility and Sterility
Volume 91, Issue 4 , Pages 1067-1076, April 2009

Article Tools

* Image Usage & Resolution